Sign In
Buy BMRN
$60.02
-0.560 (-0.92%)
At Close: Jul 31, 2026
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
10:46am, Tuesday, 13'th Jan 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now?
10:41am, Tuesday, 13'th Jan 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
06:25pm, Monday, 12'th Jan 2026
BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioMarin Appoints Arpit Davé Chief Digital and Information Officer
04:05pm, Monday, 12'th Jan 2026
Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
10:40am, Monday, 12'th Jan 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veeva und BioMarin schließen langfristige strategische Partnerschaft
06:07am, Friday, 09'th Jan 2026
/PRNewswire/ -- Veeva Systems (NYSE: VEEV) und BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) gaben eine langfristige Unternehmensvereinbarung bekannt, die auf
SAN RAFAEL, Calif., Jan. 8, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at th
Veeva y BioMarin forman una alianza estratégica a largo plazo
11:31am, Thursday, 08'th Jan 2026
/PRNewswire/ -- Veeva Systems (NYSE: VEEV) y BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) anunciaron un acuerdo empresarial a largo plazo que se basa en su
Veeva and BioMarin Form Long-Term Strategic Partnership
08:30am, Thursday, 08'th Jan 2026
Partnership to help BioMarin increase speed and efficiency in developing and commercializing innovative therapies PLEASANTON, Calif., and SAN RAFAEL, Calif.
10 Magnificent Stocks That Can Make You Richer in 2026
04:06am, Monday, 05'th Jan 2026
The stock market's major indexes delivered, once again, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite all climbing to record highs in 2025. Regardless of whether the bull market
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of A
BALA CYNWYD, Pa. , Dec. 23, 2025 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky
What's Going On With BioMarin Stock On Tuesday?
01:05pm, Tuesday, 23'rd Dec 2025
On Friday, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) agreed to acquire Amicus Therapeutics, Inc. (NASDAQ: FOLD) for a total equity value of about $4.8 billion.
BioMarin: Amicus Buyout Sparks My Enthusiasm
03:15pm, Monday, 22'nd Dec 2025
BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example,
